In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today’s podcast is a special episode of Talking Precision Medicine, dedicated to the Alliance for Artificial Intelligence in Healthcare. The A-A-I-H saw its official hard launch at JP Morgan this past January, with a standing-room-only panel discussion at the Biotech Showcase. Our guest today is Dr. Annastasiah Mhaka, a Senior Advisor at Adjuvant Partners and the muscle behind standing up the AAIH.

The Alliance is a global organization that aims to improve patient quality of life by creating more effective, sustainable, and accessible healthcare. Through its work on education, regulatory issues, technology standards, and more, the AAIH will foster the responsible development of emerging industry segments poised to have a tremendous impact across the healthcare spectrum.

At the end of our conversation with Annastasiah, we include some bonus material recorded at The Future of AI-Powered Healthcare panel discussion at JPM.

Full disclosure— Genialis is a founding member of the AAIH, and its CEO, Rafael Rosengarten, is a board director.

Rebooting generics to fight cancer | Talking Precision Medicine #21

Talking Precision MedicineBy GenialisAug 31, 2020